---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116848"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:27:07.699995+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56

## Summary
- Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).
- LYBALVI sales $74.7M (+47%), VIVITROL $113.7M (+14%), ARISTADA $84.7M.
- GAAP net income from continuing ops $92.8M, diluted EPS $0.56; non-GAAP net income $121.4M.
- Cash & investments $927.8M; repurchased 4.4M shares for $115.6M in Q3; $200M remaining under buyback.
- Company reiterates 2024 financial expectations; advancing ALKS 2680 phase 2 studies in narcolepsy.

## SEC filing metadata
- accession: 0000950170-24-116848
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/0000950170-24-116848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/alks-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116848
- JSON: https://secwatch.observer/filing/0000950170-24-116848.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.